引用本文: | 评价者:姚和瑞, 游凯云, 文献合成者:汪颖, 余运芳. CALGB 40603研究分析: Ⅱ/Ⅲ期三阴性乳腺癌新辅助化疗加用卡铂和/或贝伐单抗提高病理完全缓解率[J]. 循证医学, 2017, 17(3): 140-145. DOI: 10.12019/j.issn.1671-5144.2017.03.006 |
Citation: | Reviewers: YAO He-rui, You Kai-yun, WANG Ying, Literature Co-workers: YU Yun-fang. The Interpretation of CALGB 40603 Trial: The Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Chemotherapy Improve Pathologic Complete Response Rates in StageⅡto Ⅲ Triple Negative Breast Cancer[J]. Journal of Evidence-Based Medicine, 2017, 17(3): 140-145. DOI: 10.12019/j.issn.1671-5144.2017.03.006 |